Autologous Peripheral Blood Stem Cell Transplantation With In Vivo Purging as an Alternate Stem Cell Transplantation Program for Pts w/AML in 1st & 2nd Complete Remission w/no HLA Matched Related Donor

This study is currently recruiting participants. (see Contacts and Locations)

Verified December 2011 by King Faisal Specialist Hospital & Research Center

Sponsor:

Information provided by (Responsible Party):

King Faisal Specialist Hospital & Research Center

ClinicalTrials.gov Identifier:

NCT00531583

First received: September 17, 2007

Last updated: December 11, 2011

Last verified: December 2011

History of Changes

Purpose

Autologous peripheral Bld Stem Cell Transplantation with In Vivo Purging as an alternate stem cell transplantation program for pts w/AML in 1st & 2nd complete remission w/no HLA matched related donor

Condition	Intervention
Leukemia, Monocytic, Acute	Drug: Autologous peripheral Bld Stem Cell Transplantation with In Vivo Purging as an alternate stem cell transplantation


Study Type:	Interventional
Study Design:	Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	Autologous Peripheral Blood Stem Cell Transplantation With In Vivo Purging as an Alternate Stem Cell Transplantation Program for Pts w/AML in 1st & 2nd Complete Remission w/no HLA Matched Related Donor

Resource links provided by NLM:

Genetics Home Reference related topics: core binding factor acute myeloid leukemia cytogenetically normal acute myeloid leukemia familial acute myeloid leukemia with mutated CEBPA

Genetic and Rare Diseases Information Center resources: Leukemia, Myeloid

U.S. FDA Resources

Further study details as provided by King Faisal Specialist Hospital & Research Center:

Primary Outcome Measures:

Efficacy [ Time Frame: 2009-2015 ] [ Designated as safety issue: No ]


Estimated Enrollment:	350
Study Start Date:	March 2001
Estimated Study Completion Date:	June 2015
Estimated Primary Completion Date:	June 2015 (Final data collection date for primary outcome measure)

Intervention Details:

Stem Cell Transplantation

stem cell transplantation

Autologous PBSCT

Eligibility


Ages Eligible for Study:	18 Years to 85 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients with AML in 1st & 2nd complete remission w/no HLA matched related donor

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00531583

Contacts


Contact: Fahad AlMohareb, MD		fmohareb@kfshrc.edu.sa

Locations


Saudi Arabia
KFSH&RC	Recruiting
Riyadh, Saudi Arabia, 1211
Contact: Fahad AlMohareb, MD

Sponsors and Collaborators

King Faisal Specialist Hospital & Research Center

Investigators


Principal Investigator:	Fahad AlMohareb	KFSH&RC

More Information

No publications provided


Responsible Party:	King Faisal Specialist Hospital & Research Center
ClinicalTrials.gov Identifier:	NCT00531583 History of Changes
Other Study ID Numbers:	RAC#2001-004
Study First Received:	September 17, 2007
Last Updated:	December 11, 2011
Health Authority:	ORA: KFSH&RC, Riyadh, Saudi Arabia

Keywords provided by King Faisal Specialist Hospital & Research Center:


AML in 1st & 2nd complete remission w/no HLA matched related donor

Additional relevant MeSH terms:


Leukemia, Monocytic, Acute Leukemia Leukemia, Myeloid	Leukemia, Myeloid, Acute Neoplasms Neoplasms by Histologic Type

ClinicalTrials.gov processed this record on March 03, 2015

To Top